Skip to content
DataLookout
Menu

LLSATNCT04167358

Linerixibat Long-term Safety, and Tolerability Study

StatusCompleted
PhasePhase 3
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 39 versions: 38 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 19 words Show 4 more changesShow less
    • Trial completed
    • Start date: Jul 14, 2020 to Jul 8, 2020
    • Secondary endpoints: details revised at 8 of 9 entries
    • Site details revised at 18 of 94 sites
  2. Minor Trial sites expanded: 89 → 94 locationsv38
  3. Minor Enrollment target: 245 to 242
    • Study sites: 95 to 89
    • Primary and study completion dates: Aug 31, 2027 to Sep 30, 2026
    v37
  4. Minor Site details revised at 3 of 95 sitesv36
  5. Minor Enrollment target: estimated 251 to confirmed 245v35
Show 32 earlier versionsHide 32 earlier versions
  1. Notable Primary and study completion dates: Feb 2, 2027 to Aug 31, 2027
    • Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 94 to 95
    v34
  2. Minor Site details revised at 9 of 94 sitesv33
  3. Minor Enrollment target: 305 to 251
    • Study sites: 111 to 94
    v32
  4. Notable Primary and study completion dates: Dec 23, 2025 to Feb 2, 2027
    • Study sites: 52 to 111
    v31
  5. Minor Study sites: 48 to 52v30
  6. Minor Study sites: 42 to 48v29
  7. Minor Study sites: 30 to 42v28
  8. Notable Eligibility criteria expanded, about 8 words
    • Secondary endpoints revised (9)
    v27
  9. Minor Study sites: 28 to 30v26
  10. Minor Study sites: 27 to 28v25
  11. Notable Primary and study completion dates: Dec 9, 2024 to Dec 23, 2025
    • Study sites: 26 to 27
    v24
  12. Notable Enrollment target: 75 to 305v23 Show 4 more changesShow less
    • Eligibility criteria shortened, about 265 words
    • Study sites: 24 to 26
    • Secondary endpoints: 8 to 9
    • Study title revised
  13. Minor Study sites: 22 to 24v22
  14. Minor Study sites: 21 to 22v21
  15. Minor Study sites: 19 to 21v20
  16. Minor Study sites: 18 to 19v19
  17. Minor Study sites: 17 to 18v18
  18. Minor Study sites: 12 to 17
    • Start date: Jul 8, 2020 to Jul 14, 2020
    v17
  19. Minor Study sites: 11 to 12v16
  20. Minor Study sites: 10 to 11v15
  21. Minor Study sites: 6 to 10v14
  22. Minor Study sites: 5 to 6v13
  23. Minor Study sites: 4 to 5v12
  24. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 1 to 4
    • Primary and study completion dates: Dec 24, 2024 to Dec 9, 2024
    • Start date changed from estimate of Jul 6, 2020 to Jul 8, 2020
    v11
  25. Notable Start date: Jun 2, 2020 to Jul 6, 2020
    • Study sites: 0 to 1
    • Primary and study completion dates: Nov 20, 2024 to Dec 24, 2024
    v10
  26. Minor Primary and study completion dates: Oct 22, 2024 to Nov 20, 2024
    • Start date: May 4, 2020 to Jun 2, 2020
    v9
  27. Notable Start date: Apr 2, 2020 to May 4, 2020
    • Primary and study completion dates: Sep 20, 2024 to Oct 22, 2024
    v8
  28. Minor Primary and study completion dates: Sep 9, 2024 to Sep 20, 2024
    • Start date: Mar 20, 2020 to Apr 2, 2020
    v7
  29. Minor Primary and study completion dates: Aug 22, 2024 to Sep 9, 2024
    • Start date: Mar 4, 2020 to Mar 20, 2020
    v6
  30. Notable Eligibility criteria expanded, about 7 words
    • Enrollment target: 80 to 75
    • Secondary endpoints: 7 to 8
    v5
  31. Notable Start date: Jan 20, 2020 to Mar 4, 2020
    • Primary and study completion dates: Jul 1, 2024 to Aug 22, 2024
    v4
  32. Minor Start date: Jan 10, 2020 to Jan 20, 2020v3
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Number of participants with non-serious adverse events (AEs) and Serious AEs (SAEs)
Timeframe: Up to 66 months
Number of participants with Severe AEs
Timeframe: Up to 66 months

Secondary (9)

Change in domain scores of the PBC-40 over time
Change in health-related quality of life (QoL) by the Euro Quality-5 dimension-3 level (EQ-5D-3L) scores over time (Group 1 only)
Change in self-rated health by EQ VAS scores over time (Group 1 only)
Change in the Beck Depression Inventory (BDI-II) scores over time
Number of participants with clinically significant changes in hematology, biochemistry (including lipid and liver parameters), and coagulation parameters
Show 4 moreShow less
Percentage of responders at Week 24 and Week 52 of continuous treatment (Group 2 only)
Percentage of participants with maintenance of efficacy at Week 52 of continuous treatment in those that were responders at Week 24 of continuous treatment (Group 2 only)
Change from Baseline Monthly Sleep Score (MSS) (Group 2 only)
Change from Baseline in Monthly Fatigue Score (MFS)(Group 2 only)

Arms and interventions

Participants receiving linerixibatExperimental

Participants who previously participated in the Phase 2 studies (BAT117213 and 201000 GLIMMER \[Group 1\]) and Phase 3 study (212620 GLISTEN \[Group 2\]), will receive linerixibat.

Drugs: Linerixibat

Sites

94 sites in 17 countries

Japan 19, United States 11, China 9, United Kingdom 9, Italy 8, Argentina 6, Poland 5, Spain 5, Brazil 4, Israel 4, Mexico 3, Russia 3, Canada 2, Czechia 2, Germany 2, Bulgaria 1, France 1